Skip to main content

Medicines optimisation

As people live longer with multiple long-term conditions, effective medicines optimisation becomes crucial. In England, over 70% of individuals aged 75 and above take at least three prescribed medications. While polypharmacy can be beneficial, it’s essential to manage it carefully to avoid drug-related harm and ensure overall wellbeing.

We focus on developing and refining approaches that ensure the safe and effective use of multiple medications for individuals with complex health conditions. Our work aims to address the challenges of managing polypharmacy, improve the quality of life for patients, and support healthcare professionals with innovative solutions. 

Our work

  • Liverpool Drug Interactions Resources: Our award-winning tools provide comprehensive support for managing drug interactions, with a focus on HIV, Hepatitis and COVID-19. These resources include a suite of websites and apps that offer evidence-based recommendations and access to an extensive database of drug interactions.  
  • Multimorbidity and Medicines Evaluation: This research explores the inclusion of older, multimorbid adults in clinical trials to develop therapies that are safe and effective for diverse real-world health profiles. 
  • DynAIRx programme: Funded by the NIHR, this programme is creating AI-driven tools to help optimise prescribing practices and integrate care for patients with multiple long-term conditions. 
     
Lauren Walker

At the forefront of medicines optimisation, we are dedicated to developing innovative approaches that ensure the safe and effective use of multiple medications for individuals with complex health needs.

Dr Lauren Walker, Reader in Clinical Pharmacology & Therapeutics and Internal Medicine
Drugs and medicines placed on world map

Spotlight: Improving drug-drug interactions management with digital prescribing tools

Addressing the complex landscape of drug-drug interactions (DDIs) is crucial for ensuring the effectiveness of treatments and the safety of patients. To tackle this challenge, the Liverpool Drug Interactions Group, led by Professor Saye Khoo, has developed specialised online prescribing tools for identifying and managing DDIs in patients with HIV, hepatitis and COVID-19.